On the 24th of August 2001, a group of business and licensing executives united in Basel and founded the Swiss Pharma Licensing Group. The first Board defined objectives, recruited members and set up the foundation for today’s association.
Following a long time collaboration between our associations, the Swiss HLG is joining the Italian HLG to co-organize the Summer Conference 2019 in Milan, Italy.
A great program with experts from Italy, Switzerland and the UK will be discussing “Trends in Business Development & Licensing in the Pharmaceutical and Healthcare industry.”
Networking opportunities are planned to facilitate business contacts and discussions during our social events with cocktail, dinner and a walk in the Navigli area in Milan.?
For more detailed information on the program and speakers click here
When: 6th – 7th June 2019
Where: Art Hotel Navigli, Via Angelo Fumagalli, 4, 20143 Milan
The 2019 Swiss Healthcare Licensing Group (HLG) Winter Conference focused on the topic “Capture Deal Value – When and How?”
The pharmaceutical industry is facing increasing challenges to cope with the quickly changing world economy. The requirements in healthcare are becoming ever more demanding considering the higher standard of data, financial investments and time, let alone governments` cost-containment measures getting more restrictive.
Both new and innovative molecules in the pipeline and growing access of patients to drug treatment especially in emerging markets are at the same time positive signals though. It seems that the pharmaceutical industry still finds room for creative ways to explore and implement new business models keeping pace with current changes in the healthcare environment.
Over three days, nearly 100 delegates from Switzerland, Europe, the US and Asia gathered in the Gruyère region to explore current and future innovative ways when and how to capture maximum deal value.
Conference Director, Ragip Ziyal with the active support of the entire Swiss HLG Board, gathered a global forum of high caliber speakers not only from the healthcare and consumer industry but also governmental initiatives to capture the maximum value for assets in the best manner and at the right time by (I) learning how synergies may be exploited for example during M&A transactions, (II) discussing the need for strategic access to new technologies and (III) looking at new players such as new public and public-private funding schemes as well as patient and non-profit organizations to support R&D funding.
Prior to the start of the conference, Marie Petit, Villiger Valuation Expert, and Partner orchestrated an interactive workshop to understand “Value of Sciences vs. Value of Cash” and so to decrypt the reasons behind using rNPV or VC methodologies to value projects or biotech companies.
In her opening keynote, Allison Jeynes-Ellis, CEO Avillion LLP, excellently set the scene by providing an innovative model on how the drug development, as well as the commercial risk, can be shared whereby Avillion is funding the clinical programme and receiving returns upon regulatory success and providing off-balance relief to the pharma partner.
The second day started with four distinct speakers exploring how synergies may be exploited in the pharmaceutical industry. Thomas Hafen, CEO Bühlmann Labs outlined the opportunities but also challenges when capturing value with point-of-care diagnostics. Tim Schlange, Chief Marketing Officer at Lohmann Therapy Systems (LTS), followed with a focus on leveraging synergies between pharma and CDMO through innovative transdermal/-mucosal delivery technologies. Dominique Doyen, Director Business Development at 4SC underlined how partnerships can result in a business model at biotech along with Jochen Hurlebaus, Head of Central R&D Services, Innovation & IP at Roche Diagnostics who rather concentrated on accessing new technologies and thus securing value by getting access to digital innovation.
In a dynamic panel discussion, Ton Berkien, CBO at Nuevolution and former Head of M&A Emerging Markets at Takeda, Charles Hoare, Managing Director and Head of European Healthcare at Stiefel, Jordi Sabé, Founding Partner at Evolve Healthcare and former SVP Corporate Development at Almirall and Roberto Tracia, Partner at Oaklins Binder, all with a total of more than 80 years experience in international M&A transactions shared their view on synergies, which may be seen as one of the major motivators for M&A. They also discussed key success factors and challenges during the integration of assets post-M&A.
The topic capturing value through the strategic access to new technologies dominated the second half of the second day. Sascha Bucher, VP and Head of Global Transactions at Roivant Sciences highlighted Roivant`s ecosystem built on entrepreneurial biotech companies, the so-called Vants, a unique approach to source talents and to deploy technology to strive for efficient R&D and commercialization. Matthias Essenpreis, CTO at Roche Diagnostics described the dependency on external innovation, Roche Diagnostics being as the global leader in in vitro diagnostics and how dedicated processes were established to cope with this very challenge.
After a full day of inspiring presentations and the panel discussion, the delegates enjoyed a typical Swiss Fondue Dinner in an authentic Swiss barn nearby. It was a perfect setting to network with peers and exchange personal and professional experiences.
The last day of the conference focused on innovative financing in the pharmaceutical industry, starting with David Hughes, Senior Global Programme Head at Novartis` Anti-Infectives Global Health Development Unit. David gave an overview of publicly-funded models like EU`s Innovative Medicines Initiative (IMI) or US Government`s Biomedical Advanced R&D Authority (BARDA) established to close gaps in some key disease areas targeting anti-microbial resistance and neglected tropical diseases. Marc Gitzinger, CEO at Bioversys focused in his speech on financing and deal-making in the antibiotic market, which seems a broken economic model where initiatives established both the so-called “Push” funding and “Pull” mechanisms to fix the economic model for novel antibiotics. Finally, Stefan Fischer, National Contact Point (NCP) at Euresearch stressed the importance of public bottom-up funding like the Horizon 2020 financing opportunities for innovative SMEs with game-changing and market-creating innovations and technologies.
The outstanding closing keynote, delivered by Ernst Hafen, Professor of Systems Genetics at ETH Zurich and the President of the Biopark Zurich-Schlieren, the value of citizen-controlled health data. Ernst thereby underlined that we have to regain control over our data thus our digital self-determination and reduce our dependency on multinational data companies, which may determine our faith in the future.
The Swiss HLG Board sincerely expresses its thanks to the presenters and the attendees for the lively discussions and interactions. Without them the success of the Winter Conference would not have been possible. Please find below some images from the conference. Please click on the image to view it in its entirety. (Please click on the image to view it in its entirety and or a slide show.)
Special Swiss HLG offer!
* €100 discount for the first 10 Swiss HLG Members that register – discount code: 10SwissHLG
* €150 discount for the first 10 Swiss HLG Start-Up Members that register – discount code 10SUSwissHLG
**The codes should be entered in the ‘Submit Promotion Code’ box on the payments page
| Swiss HLG, member of the European Pharma Licensing Council (EPLC), invites you to join the International Pharma Licensing Symposium in Paris Without question we live in interesting times, the 15th IPLS has been designed to explore some of the more disruptive influences and opportunities in the life science industry today. Two days of informative presentations from industry leading speakers, peer to peer networking, one-to-one meeting opportunities and continuous personal development, all in the world’s most popular and dynamic city, Paris. Conference Programme Includes: Contemporary Trends in Pharma Business Development Artificial Intelligence Medical Cannabis Evolution of Business Development Teams The Continuum of Ageing & Age-Related Diseases Ageing Opportunities in Pharmaceuticals New Therapeutic Advances And much more, including 7 hours of dedicated one-to-one partnering Full Programme & Event Website REGISTER ONLINE NOW |
| XV International Pharma Licensing Symposium Pullman Hotel Paris Centre – Bercy Paris, France Wednesday 18th to Friday 20th September 2019 Who Should Attend? Business Development Professionals, Managing Directors, General Managers, Business Owners, Investors, Advisors, Financial, Marketing& Regulatory Executives REGISTER ONLINE NOW |
Basel, 16th February 2018 – The Swiss HLG, a non-profit association of Business Development and Licensing professionals, held its 27th Conference titled “ Reset Partnering – Step out of the Box!” With partnering deals increasing in complexity, the evolution from pharmaceuticals to solutions and the consumerization of healthcare, Business Development, and Licensing professionals need to ask themselves if the tools and approaches used are still fit for purpose in the healthcare world of 2018.
Over three days, more than 100 delegates from Switzerland, Europe, the US and Asia gathered in the Swiss Alps to explore and exchange on the future of partnering and to take a step out of the Box.
Conference Director, Chris Isler with the active support of the entire Swiss HLG Board, convened a global panel of leading experts from the healthcare and consumer industry addressing three main questions:
Before the start of the conference, Anthony A. Hörning, CEO of Strategic Transactions Advisor and former head of Alliance Management at Novartis led a dynamic and interactive workshop helping participants to understand “What happens after marriage – managing complex alliances”.
As an introduction, Jean-Paul Clozel, CEO of Idorsia and former CEO of Actelion, brilliantly set the stage with his thought-provoking keynote speech on his company has been acquired by Johnson & Johnson, despite not willing himself to sell it. He brought the audience to think on how the relationship and trust dimension were important to make such a transaction a success.
Francesco De Rubertis, CEO of the Medicxi Venture Fund expanded on Clozel’s thoughts with the view from the VC’s perspective and explained how entrepreneurialism and venture capital could go hand in hand. He shared his opinion as VC vs JP Clozel vision as an entrepreneur.
One of the Swiss HLG objectives is not just professional but also personal development, and hence Design Thinking Master, Rana Lonnen, Head Search and Evaluation Strategic Venture Capital at Novartis Pharma opened the day on Monday exploring how design thinking approaches can be leveraged in a partnering setting.
Six captivating presentations illustrated then what, along with the partnering process, is required to find the right deal. Alan Selby, Executive Director at Torreya Partners, shared his thoughts on when to use a broker or not. Emma Barton, Director Alliance, and Integration Management at AstraZeneca explained how Outlicensing can preserve the value of a molecule. Shigeo Taniuchi, Head of EMEA, Senior Corporate officer at Santen Pharmaceutical and Viren Mahurkar, formerly at Alcon took a look at the cultural dimension of partnerships and what to bear in mind when working with partners in Japan or China.
Tanja Dowe, CEO of the Debiopharm Innovation Fund focused on how to find the right deal with a VC fund and last but not least Vikalp Mohan, Vice President Sales and Marketing at Celonic took a look at how to partner with a Contract Development and Manufacturing Organization.
After a full day of presentations, the delegates enjoyed a short walk and typical Swiss Fondue Dinner in a barn and used the opportunity to expand their personal and professional networks.
The last day of the conference focused on how to partner beyond the molecules, starting with a case study looking at how to make more out of data by Dr. Alexandra V. Eberhard, Managing Director Europe, and Executive VP Sciences at Signals Analytics. Michael Meissner, Chief Technology Officer, at Sanofi took a look at how technology is becoming increasingly important for pharma and asked the question if pharma in this picture is the boiling frog. Ravi Sodha, Senior Director, Business Development at Actelion closed this block in sharing his perspectives on what makes deals for rare diseases different.
The closing keynote, delivered by Jon Otterstatter, CEO of the Preventice Solutions Group took the audience along the journey of building a highly successful medical technology start-up from scratch to a 500+ employee organization with prominent investors such as Merck Inc or Boston Scientific.
The Swiss HLG Board thanks the presenters and the participants for the lively discussion and interactions. Please find below some images from the conference. (Please click on the image to view it in its entirety and or a slide show.)
